8-K current report · filed Nov 9, 2026

Maze Therapeutics, Inc. (MAZE) 8-K Current Report: November 9, 2026

Item 2.02Item EX-99.1MAZE overview

Short answer

Maze Therapeutics, Inc. (MAZE) filed an 8-K current report with the SEC on November 9, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 financial results for quarter ended September 30, 2026.

Maze Therapeutics, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q3 2026 financial results for quarter ended September 30, 2026
  • Full results and management commentary available in Exhibit 99.1 press release
  • Investor focus: cash runway, R&D spending, pipeline progress, and any updated guidance

Item EX-99.1 · Exhibit EX-99.1

  • Q3 net loss widened to $48.0M, or $0.79 per share, from $30.1M, reflecting accelerated clinical investment
  • Cash, equivalents and marketable securities reached $477.0M, supporting projected operations into 2029
  • MZE829 HORIZON enrollment exceeded target with more than 50 patients; complete data expected early 2027
  • MZE829 pivotal trial planned for H1 2027, subject to regulatory feedback, creating a near-term development catalyst
  • MZE782 PKU enrollment continues, with topline data expected in 2027 and CKD Phase 2 initiation targeted for H1 2027

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Maze Therapeutics, Inc. 8-K filings

Get the next MAZE 8-K as it lands

Follow MAZE for push alerts, or ask the research agent what this filing means.